SELLAS Life Sciences Falls Overnight After Discounted Share Offering
· 3 sources
SELLAS Life Sciences (SLS) dropped in overnight and pre-market trading after a share offering priced at a discount following positive leukemia trial results.
What happened
SELLAS Life Sciences Group (SLS) shares fell in overnight trading after the company announced a share offering priced at a discount, according to Stocktwits and Yahoo Finance. The move came right after positive results from a leukemia trial.
Yahoo Finance reports that the offering price was still 74% above Monday's close, and that the trial results had sent shares up 156% on Tuesday. Stocktwits describes the discount as nearly 30%, and notes the offering tested the patience of retail investors who had been bullish after the acute myeloid leukemia (AML) trial win.
Kalkine Media lists SELLAS among its pre-market movers for November 19, 2026, reporting a decline of 19.61% for the stock. Yahoo Finance adds that some retail investors criticized the offering price as very low.
Context
Companies, especially clinical-stage biotechs, often raise capital through share offerings after positive trial data, which increases the number of shares outstanding.
Why it matters
The episode shows how a financing announcement can shape market reaction to a company even after strongly positive clinical news.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
39%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $11.63 and $21.50; 9 in 10, between $6.74 and $37.08.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy